Literature DB >> 14502009

Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?

Gavin J Churchyard1, Katherine Fielding, Salome Charalambous, John H Day, Elizabeth L Corbett, Richard J Hayes, Richard E Chaisson, Kevin M De Cock, Badara Samb, Alison D Grant.   

Abstract

OBJECTIVE: To determine the efficacy of secondary preventive therapy against tuberculosis (TB) among gold miners working in South Africa.
DESIGN: An observational study.
SETTING: Health service providing comprehensive care for gold miners.
METHODS: The incidence of recurrent TB was compared between two cohorts of HIV-infected miners: one cohort (n = 338) had received secondary preventive therapy with isoniazid (IPT) and the other had not (n = 221).
RESULTS: The overall incidence of recurrent TB was reduced by 55% among men who received IPT compared with those who did not (incidence rates 8.6 and 19.1 per 100 person-years, respectively; incidence rate ratio, 0.45; 95% confidence interval 0.26-0.78). The efficacy of isoniazid preventive therapy was unchanged after controlling for CD4 cell count and age. The number of person-years of IPT required to prevent one case of recurrent TB among individuals with a CD4 cell count < 200 x 106 cells/l, and > or = 200 x 106 cells/l was 5 and 19, respectively.
CONCLUSION: Secondary preventive therapy reduces TB recurrence: the absolute impact appears to be greatest among individuals with low CD4 cell counts. International TB preventive therapy guidelines for HIV-infected individuals need to be expanded to include recommendations for secondary preventive therapy in settings where TB prevalence is high.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502009     DOI: 10.1097/00002030-200309260-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.

Authors:  Florian M Marx; Sian Floyd; Helen Ayles; Peter Godfrey-Faussett; Nulda Beyers; Ted Cohen
Journal:  Eur Respir J       Date:  2016-07-07       Impact factor: 16.671

Review 2.  HIV and tuberculosis coinfection: inextricably linked liaison.

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

3.  Epidemiology of Respiratory Disease in Malawi.

Authors:  Stephen Gordon; Stephen Graham
Journal:  Malawi Med J       Date:  2006-09       Impact factor: 0.875

4.  Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.

Authors:  Florian M Marx; Ted Cohen; Nicolas A Menzies; Joshua A Salomon; Grant Theron; Reza Yaesoubi
Journal:  Lancet Glob Health       Date:  2020-09       Impact factor: 26.763

Review 5.  HIV-associated tuberculosis and cryptococcosis in resource-limited settings.

Authors:  Umesh G Lalloo; Farida C Amod
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

Review 6.  Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection.

Authors:  Asha Anandaiah; Keertan Dheda; Joseph Keane; Henry Koziel; David A J Moore; Naimish R Patel
Journal:  Am J Respir Crit Care Med       Date:  2010-12-22       Impact factor: 21.405

7.  Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010.

Authors:  Thuy T Trinh; Dien T Han; Emily Bloss; Thai H Le; Tung T Vu; Anh H Mai; Nhung V Nguyen; Long T Nguyen; Sy N Dinh; Sara Whitehead
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-10       Impact factor: 2.184

Review 8.  Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment.

Authors:  Kerry L Dierberg; Richard E Chaisson
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 9.  Epidemiology of HIV-associated tuberculosis.

Authors:  Stephen D Lawn; Gavin Churchyard
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

Review 10.  Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Authors:  Stephen D Lawn; Katharina Kranzer; Robin Wood
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.